NPI: 1043263999 · WILD ROSE, WI 54984 · Critical Access Hospital · NPI assigned 05/19/2006
Authorized official FLETT, WILLIAM controls 20+ related entities in our dataset. Read more
| Authorized Official | FLETT, WILLIAM (CFO) |
| NPI Enumeration Date | 05/19/2006 |
Other providers sharing the same authorized official: FLETT, WILLIAM
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 14,414 | $775K |
| 2019 | 11,062 | $964K |
| 2020 | 13,516 | $632K |
| 2021 | 15,966 | $732K |
| 2022 | 17,071 | $809K |
| 2023 | 19,335 | $1.11M |
| 2024 | 13,394 | $1.01M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 7,073 | 5,746 | $1.41M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 3,680 | 2,846 | $897K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1,395 | 1,082 | $893K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3,377 | 2,871 | $866K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1,156 | 967 | $502K |
| 70450 | Computed tomography, head or brain; without contrast material | 629 | 528 | $224K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 723 | 559 | $189K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 624 | 406 | $178K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 389 | 284 | $144K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 736 | 631 | $141K |
| 80048 | Basic metabolic panel (calcium, ionized) | 9,233 | 6,867 | $89K |
| 83880 | 2,295 | 1,757 | $49K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 8,227 | 6,303 | $45K |
| 87631 | 552 | 452 | $44K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1,851 | 1,627 | $33K |
| 80076 | 6,056 | 4,798 | $32K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 767 | 658 | $29K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 107 | 77 | $27K |
| 84484 | 3,200 | 1,966 | $19K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,246 | 2,434 | $17K |
| 71046 | Radiologic examination, chest; 2 views | 636 | 500 | $16K |
| 80306 | 993 | 811 | $14K | |
| 80061 | Lipid panel | 1,211 | 1,129 | $13K |
| 83735 | 3,320 | 2,563 | $12K | |
| 83690 | 2,082 | 1,696 | $10K | |
| 81001 | 4,267 | 3,444 | $10K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 206 | 163 | $10K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 581 | 230 | $9K |
| 82550 | 2,591 | 2,006 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1,092 | 927 | $9K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 26 | 24 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | 891 | 838 | $7K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 487 | 423 | $7K |
| 85610 | 3,217 | 2,320 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 220 | 194 | $7K |
| 82553 | 1,688 | 1,310 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2,825 | 2,215 | $5K |
| 86140 | 1,447 | 1,164 | $5K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 289 | 77 | $5K |
| 82077 | 515 | 395 | $5K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 12 | 12 | $4K |
| 82150 | 567 | 477 | $3K | |
| 71045 | Radiologic examination, chest; single view | 1,855 | 1,478 | $3K |
| 85380 | 416 | 344 | $2K | |
| 36415 | Collection of venous blood by venipuncture | 7,278 | 5,601 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 25 | 25 | $2K |
| 99000 | 489 | 332 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 17 | 15 | $2K |
| 81025 | 79 | 77 | $2K | |
| 83605 | 284 | 206 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 109 | 94 | $2K |
| 85379 | 276 | 226 | $1K | |
| 87070 | 113 | 95 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1,860 | 1,427 | $923.54 |
| 87634 | 15 | 14 | $912.19 | |
| 84703 | 145 | 123 | $859.58 | |
| 87040 | 109 | 48 | $410.04 | |
| 87650 | 14 | 13 | $309.08 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 41 | 36 | $231.99 |
| 36592 | 171 | 137 | $163.34 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,934 | 1,584 | $125.68 |
| 87088 | 36 | 27 | $123.96 | |
| 80143 | 18 | 12 | $120.63 | |
| 87186 | 18 | 13 | $60.49 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 899 | 735 | $35.01 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,087 | 847 | $17.89 |
| A9270 | Non-covered item or service | 143 | 87 | $14.43 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 66 | 51 | $10.65 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 130 | 87 | $6.20 |
| J7050 | Infusion, normal saline solution, 250 cc | 504 | 261 | $3.93 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 412 | 314 | $0.03 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 1,676 | 1,356 | $0.01 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 13 | 12 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 14 | 13 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 16 | 13 | $0.00 |
| 96376 | 17 | 12 | $0.00 |